Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types | Zendy

Arielle L. Heeke | Zendy; Michael J. Pishvaian | Zendy; Filipa Lynce | Zendy; Joanne Xiu | Zendy; Jonathan R. Brody | Zendy; Wang-Juh Chen | Zendy; Tabari Baker | Zendy; John L. Marshall | Zendy; Claudine Isaacs | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types

Author(s) -

Arielle L. Heeke,

Michael J. Pishvaian,

Filipa Lynce,

Joanne Xiu,

Jonathan R. Brody,

Wang-Juh Chen,

Tabari Baker,

John L. Marshall,

Claudine Isaacs

Publication year - 2018

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.17.00286

Subject(s) - palb2 , fanca , ercc1 , homologous recombination , bap1 , rad51 , mlh1 , cancer research , gene , biology , dna repair , medicine , genetics , germline mutation , mutation , dna mismatch repair , fanconi anemia , nucleotide excision repair

The prevalence of homologous recombination DNA damage repair (HR-DDR) deficiencies among all tumor lineages is not well characterized. Therapy directed toward homologous recombination DDR deficiency (HRD) is now approved in ovarian and breast cancer, and there may be additional opportunities for benefit for patients with other cancers. Comprehensive evaluations for HRD are limited in part by the lack of a uniform, cost-effective method for testing and defining HRD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research